A Review of Advances in the Surgical Treatment of Coronary Heart Disease and Lung Cancer

Abstract

Lung cancer is currently the most prevalent and fatal malignant tumor in China. Additionally, the incidence of coronary heart disease is steadily increasing. Both diseases exhibit a higher risk of mortality with age, particularly among elderly patients. Moreover, these diseases are interconnected and share common risk factors. However, the treatment options for patients suffering from both lung cancer and coronary heart disease lack clarity and standardized criteria. This article critically examines the literature on surgical interventions for patients with lung cancer complicated by coronary artery disease during the period from January 2021 to December 2022. It summarizes the safety and effectiveness of these interventions and highlights the various surgical options available for different patient profiles.

Neoadjuvant therapy bridging percutaneous coronary intervention (PCI) and video-assisted thoracoscopic (VATS) lobectomy: a retrospective study

“…Simultaneous CABG has one or two surgical incisions under general anesthesia and effectively avoids the delay in lung cancer treatment, but carries a higher risk of perioperative mortality and complications, and presents technical difficulties in removing mediastinal lymph nodes. Therefore, the selection of surgical methods should be determined based on the patient’s condition and requirement ( 14 ). Therefore, exploring a new treatment method that is minimally invasive, with fewer complications, and simultaneously adheres to the principles of oncology treatment has certain clinical significance.…”